Sight Sciences Q3 revenue beats expectations, raises 2025 guidance

Overview

• Sight Sciences Q3 2025 revenue beats analyst expectations despite a 1% yr/yr decline

• Company raises full-year 2025 revenue guidance to $76-78 mln, up from $72-76 mln

• Operating expenses decreased 11% yr/yr in Q3 2025, including $2.8 mln in restructuring costs

Outlook

• Sight Sciences raises 2025 revenue guidance to $76.0 mln to $78.0 mln

• Company reduces 2025 adjusted operating expenses guidance to $90 mln to $92 mln

• Company expects tariffs to increase Surgical Glaucoma costs by $1.0 mln to $1.5 mln in 2025

Result Drivers

• SURGICAL GLAUCOMA GROWTH - Revenue growth driven by increased ordering accounts and higher average selling prices, despite coverage restrictions

• DRY EYE REVENUE DECLINE - Significant decline due to focus on achieving reimbursed market access for TearCare procedures

• OPERATING EXPENSE REDUCTION - Operating expenses decreased due to restructuring and cost management efforts

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Sight Sciences Inc is $4.00, about 25.8% below its November 5 closing price of $5.03

Press Release: ID:nGNX6xypCY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)